Literature DB >> 6303568

In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants.

D N Carney, J B Mitchell, T J Kinsella.   

Abstract

The in vitro response to radiation and chemotherapeutic drugs of cell lines established from 7 patients with small cell (SC) lung cancer were tested using a soft agarose clonogenic assay. Five cell lines retained the typical morphological and biochemical amine precursor uptake decarboxylation characteristics of SC, while two cell lines had undergone "transformation" to large cell (LC) morphological variants with loss of amine precursor uptake decarboxylation cell characteristics of SC. The radiation survival curves for the SC lines were characterized by D0 values ranging from 51 to 140 rads and extrapolation values (n) ranging from 1.0 to 3.3. While the D0 values of the radiation survival curves of the LC variants were similar (91 and 80 rads), the extrapolation values were 5.6 and 11.1 In vitro chemosensitivity testing of the cell lines revealed an excellent correlation between prior treatment status of the patient and in vitro sensitivity or resistance. No correlation was observed between in vitro chemosensitivity and radiation response. These data suggest that transformation of SC to LC with loss of amine precursor uptake and decarboxylation characteristics is associated with a marked increase in radiation resistance (n) in vitro. The observation of a 2- to 5-fold increase in survival of the LC compared to the SC lines following 200 rads suggests that the use of larger daily radiation fractions and/or radiation-sensitizing drugs might lead to a significantly greater clinical response in patients with LC morphology. This clinical approach may have a major impact on patient response and survival.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6303568

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Impact of prolonged fraction dose-delivery time modeling intensity-modulated radiation therapy on hepatocellular carcinoma cell killing.

Authors:  Xiao-Kang Zheng; Long-Hua Chen; Xiao Yan; Hong-Mei Wang
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

2.  Modulation of neuroendocrine surface antigens in oncogene-activated small cell lung cancer lines.

Authors:  L A Doyle; M Mabry; R A Stahel; R Waibel; L H Goldstein
Journal:  Br J Cancer Suppl       Date:  1991-06

3.  Cooperation of c-raf-1 and c-myc protooncogenes in the neoplastic transformation of simian virus 40 large tumor antigen-immortalized human bronchial epithelial cells.

Authors:  A M Pfeifer; G E Mark; L Malan-Shibley; S Graziano; P Amstad; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

Review 4.  Studying lung cancer in the laboratory: 3--Use of cell lines to investigate the biology of lung cancer.

Authors:  R J Fergusson; J F Smyth
Journal:  Thorax       Date:  1987-12       Impact factor: 9.139

Review 5.  Radiogenomics predicting tumor responses to radiotherapy in lung cancer.

Authors:  Amit K Das; Marcus H Bell; Chaitanya S Nirodi; Michael D Story; John D Minna
Journal:  Semin Radiat Oncol       Date:  2010-07       Impact factor: 5.934

6.  Differential expression of intermediate filament proteins distinguishes classic from variant small-cell lung cancer cell lines.

Authors:  J L Broers; D N Carney; L de Ley; G P Vooijs; F C Ramaekers
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

7.  Establishment, growth properties, and morphological characteristics of permanent human small cell lung cancer cell lines.

Authors:  G Bepler; G Jaques; K Neumann; G Aumüller; C Gropp; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

8.  Radioimmunotherapy of small-cell lung cancer xenografts using 131I-labelled anti-NCAM monoclonal antibody 123C3.

Authors:  H B Kwa; A H Verhoeven; J Storm; N van Zandwijk; W J Mooi; J Hilkens
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

9.  Relationships between various uses of antineoplastic drug-interaction terms.

Authors:  G L Wampler; W H Carter; E D Campbell; P A Keefe
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 10.  Modern management of small-cell lung cancer.

Authors:  Roberta Ferraldeschi; Sofia Baka; Babita Jyoti; Corinne Faivre-Finn; Nick Thatcher; Paul Lorigan
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.